A Phase 3 interventional study of tilrekimig and Placebo in Asthma, sponsored by Pfizer. Recruiting at 12 sites in 2 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Asthma by Pfizer — 4 open to participants now, 4 under way, 2 of them phase 3. Asthma · Pfizer.
Among the 24 studies in Asthma by Pfizer, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 24th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →4 of the 24 studies in Asthma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Japan
Ages 12–80
Pfizer · Sites in United States, Belgium
Ages 18–65 · Healthy volunteers
Pfizer · Sites in United States, Argentina, Belgium and 12 more countries
Ages 18–75
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,100 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 48 across the 20 interventional studies, 20 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Asthma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
| NCT07660731PfizerA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Asthma by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected.
The study is seeking participants who:
The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet the following asthma criteria:
Positive bronchodilator responsiveness of or FVC >10% of the participant's predicted value at 15 - 30 minutes (or as consistent with local treatment practices) after inhaling 400 µg of salbutamol/albuterol (or equivalent SABA) at least once for spirometry conducted during screening period.
Other Inclusion Criteria:
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
Any psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study.
Prior/Concomitant Therapy:
Bronchial thermoplasty within the previous 24 months.
Prior/Concurrent Clinical Study Experience:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tilrekimig
Drug: tilrekimig
Placebo
Other: Placebo
subcutaneous injection
subcutaneous injection
Annualized asthma exacerbation rate over 52 weeks
Protocol defined asthma exacerbations require treatment with systemic steroids (oral or parenteral) for 3 consecutive days or more; an emergency room or urgent care visit (\<24 hours) that is due to asthma and requires use of systemic corticosteroids as noted above; or an in-patient hospitalization (an admission to an in-patient hospital or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.
Time frame: Baseline through Week 52
Annualized asthma exacerbation rate over 52 weeks in participants with severe asthma and with eosinophil counts ≥300 cells/µL (ie, high eosinophil subgroup)
Time frame: Baseline through Week 52
Annualized asthma exacerbation rate over 52 weeks in participants with severe asthma and with eosinophil counts <300 cells/µL (ie, medium-to-low eosinophil subgroup)
Time frame: Baseline through Week 52
Change from baseline (CFB) in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Week 52
Time frame: Baseline through Week 52
CFB in Asthma Control Questionnaire (ACQ-5) at Week 52
Time frame: Baseline through Week 52
CFB in Asthma Quality of Life Questionnaire for 12 years and older Self-Administered (AQLQ(S)-12-SA) at Week 52
Time frame: Baseline through Week 52
Annualized asthma exacerbation rate requiring Emergency Room or Urgent Care (ER/UC) visit or hospitalization over 52 weeks
Time frame: Baseline through Week 52
Time to first asthma exacerbation
Time frame: Baseline through Week 52
CFB in weekly mean Asthma Nighttime Symptom Diary (ANSD) at Week 52
Time frame: Baseline through Week 52
CFB in weekly mean Asthma Daytime Symptom Diary (ADSD) at Week 52
Time frame: Baseline through Week 52
Clinical remission at Week 52
Time frame: Week 52
CFB in pre-bronchodilator FEV1 at all time points (other than Week 52)
Time frame: Baseline through Week 52
CFB in ACQ-5 all time points (other than Week 52)
Time frame: Baseline through Week 52
CFB in AQLQ(S)-12-SA at all time points (other than Week 52)
Time frame: Baseline through Week 52
CFB in weekly mean ANSD at all time points (other than Week 52)
Time frame: Baseline through Week 52
CFB in weekly mean ADSD at all time points (other than Week 52)
Time frame: Baseline through Week 52
CFB in pre-bronchodilator % Predicted FEV1 at all time points
Time frame: Baseline through Week 52
CFB in pre-bronchodilator forced vital capacity (FVC) at all time points
Time frame: Baseline through Week 52
CFB in pre-bronchodilator % Predicted FVC at all time points
Time frame: Baseline through Week 52
CFB in pre-bronchodilator FEV1/FVC ratio at all time points
Time frame: Baseline through Week 52
CFB in post-bronchodilator FEV1 at all time points
Time frame: Baseline through Week 52
CFB in post-bronchodilator % Predicted FEV1 at all time points
Time frame: Baseline through Week 52
CFB in post-bronchodilator FVC at all time points
Time frame: Baseline through Week 52
CFB in post-bronchodilator % Predicted FVC at all time points
Time frame: Baseline through Week 52
CFB in post-bronchodilator FEV1/FVC ratio at all time points
Time frame: Baseline through Week 52
ACQ-5 response: decrease from baseline in ACQ-5 ≥0.5 at all time points
Time frame: Baseline through Week 52
AQLQ response: increase from baseline in AQLQ(S)-12-SA ≥0.5 at all time points
Time frame: Baseline through Week 52
Time to first asthma exacerbation requiring ER/UC visit or hospitalization
Time frame: Baseline through Week 52
Clinical remission at Week 24
Time frame: Week 24
Event of ≥1 asthma exacerbation over 52 weeks
Time frame: Baseline through Week 52
Event of ≥1 asthma exacerbation associated with ER/UC visit or hospitalization over 52 weeks
Time frame: Baseline through Week 52
CFB in Patient global impression of disease severity (PGI-S) at all time points
Time frame: Baseline through Week 52
Patient global impression of change in clinical status (PGI-C) at all time points
Time frame: Baseline through Week 52
Annualized asthma exacerbation rate over 52 weeks by baseline fractional exhaled nitric oxide (FeNO) subgroup (<25 parts per billion (ppb), ≥25 to <50 ppb, ≥50 ppb)
Time frame: Baseline through Week 52
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: Baseline through Week 64
Incidence of treatment-emergent serious adverse events (SAEs) and TEAEs leading to discontinuation
Time frame: Baseline through Week 64
Incidence of clinical abnormalities in clinical laboratory values, vital signs or electrocardiograms
Time frame: Baseline through Week 64
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Sep 2026 (actual). Primary completion is estimated for Jun 2029, 32 months after the start.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 32 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tilrekimig